OTC Pain

Hamacher Resource Group’s Future 50 Emerging Brands from 2017 include products that run the gamut from OTC to beauty, from eyedrops to hemorrhoid cream, all of which have set themselves apart from the pack based on sales indicators and community pharmacy distribution.

Hisamitsu America has grown from a $17 million brand in 2010 to a $119 million brand in 2017 that sold almost 700 patches per minute.

The treads may be wearing thin in the foot care category, where overall sales across U.S. multi-outlets are down by 10% or more, though there may yet be opportunity with those silver foxes making their daily mall walks. Insoles and shoe inserts have long had household penetration in the high teens among the coveted baby boomers demographic.

Camber officials said this launch is the first of several launches the company expects in the coming months from its Long Island, N.Y. facility Ascent Pharmaceuticals.

P&G executives said that the acquisition would grow its geographic scale and footprint in most of the world’s top 15 OTC markets, adding products in such categories as muscle, joint and back pain, as well as cold and headaches that the company previously lacked.

In spite of an administration that looked eager to crack down on cannabis legalization, more states, red and blue alike, continue to move forward and evolve their thinking around medical and adult-use cannabis.

The new Heel Defender orthotics are bioengineered to assist in the management of pathologies that cause heel pain.

The exit of both GSK and RB doesn't leave many companies large enough to swing Pfizer's reported asking price of $20 billion for an OTC portfolio that includes powerhouse brands Advil and Centrum.